Thymos Health
Your Psoriatic Arthritis Journey

Still swollen.
Still switching biologic after biologic.
Still no clear answers.

You're not alone. This is how psoriatic arthritis (PsA) is typically managed — and an honest look at what that journey costs, and what it leads to, over time.

~2.4M Americans are estimated to have psoriatic arthritis.1
2.5 years is the median delay from joint symptoms to a psoriatic arthritis diagnosis.2
40% of psoriatic arthritis cases go undetected even in dedicated screening studies.3
$30K is the average annual all-cause cost of care per psoriatic arthritis patient.4

How psoriatic arthritis is typically treated

Most rheumatologists and insurance plans require NSAID and Methotrexate failure before approving a biologic. Each step can take 3–6 months to fail, while joint erosion accumulates in ways that later treatment cannot undo.

Mark where you are in your journey and we'll show you the full picture.

Step 1: Your rheumatologist starts you on NSAIDs & Methotrexate
Naproxen or ibuprofen for pain, plus methotrexate 15–25mg/week as first-line DMARD
What your doctor says
"Let's start with an anti-inflammatory for pain control and methotrexate to slow down joint damage."
Inexpensive, decades of clinical experience
Doesn't treat skin disease or spinal involvement well
Scientific evidence for reducing joint damage is far less effective in psoriatic arthritis than in rheumatoid arthritis
Annual cost before insurance ~$300–$800
Providers seen before this was prescribed
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Inadequate joint response after 3+ months — escalate to a biologic
Step 2: You're approved for TNF Inhibitor Biologic
Adalimumab, etanercept, golimumab, infliximab — self-injection or infusion
What your doctor says
"Time to escalate — a TNF inhibitor targets the inflammatory driver of your joint disease directly, and can also help clear your skin."
58–78% of psoriatic arthritis patients experience 20% reduction in joint discomfort5
20–32% of patients experience 70% improvement in psoriatic arthritis symptoms5
Radiographic progression continues in ~30% despite treatment6
Annual cost before insurance ~$27,000–$32,000
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
TNF inadequate or lost response — switch drug class
Step 3: You switch to IL-17 / IL-23 Inhibitor or JAK Inhibitor
Secukinumab, ixekizumab, guselkumab, or oral upadacitinib — different mechanism than Step 2
What your doctor says
"Since the TNF inhibitor isn't fully working, let's try a drug from a different class. Many patients who don't respond to one mechanism respond well to another."
70% of patients on Secukinumab experience a 20% reduction in joint discomfort7
28% of patients on Secukinumab experience near-complete resolution of psoriatic arthritis symptoms7
Response rates are consistently lower in TNF-experienced patients6
Upadacitinib shown noninferior to adalimumab in head-to-head trial8
Annual cost before insurance ~$30,000–$36,000
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Step Therapy Leads to Worsening Joint Damage & Disability
Structural damage accrued during the pre-diagnosis and step-therapy delay, now largely irreversible
What Your Doctor says
"Your imaging shows some joint erosion that developed before we got your disease under control. We'll focus on preventing further damage from here."
7.49 yr
Average diagnostic delay worsens permanent joint damage9
27.4%
Underwent joint surgery during that delay period9
~5 yr
Before diagnosis, healthcare costs are already climbing10
$30K/yr
Average all-cause cost once psoriatic arthritis is finally diagnosed4
Diagnostic delay timeline (population-based cohort)
Diagnosed within 6 months of symptom onset 23% of patients
Diagnosed within 1 year 35% of patients
Diagnosed within 2 years 45% of patients
No improvement in delay time, 2000–2017 Unchanged
What happens while the diagnosis is pending
🔪 Surgery becomes a substitute for disease control. In a real-world cohort, the annual rate of musculoskeletal surgery was significantly higher during the diagnostic-delay period than after psoriatic arthritis was formally diagnosed and treated.9
📈 The claims history starts rising years before anyone names the disease. Healthcare costs begin increasing approximately 5 years before an eventual psoriatic arthritis diagnosis — driven substantially by MSK surgeries and unexplained joint complaints.10
🦴 Delay of even 6–12 months predicts worse function. Multiple studies link diagnostic delays of this length to structural joint damage and poorer long-term functional outcomes that later biologic therapy cannot reverse.2
🎯 Awareness gaps, not biology, drive much of the delay. Clinical awareness of psoriatic arthritis compared to rheumatoid arthritis remains poor in general community practice, contributing to slow rheumatology referral.2
⚠ The biologic ladder starts the clock too late
Step therapy sequences which conventional DMARD to try first, then which biologic — but none of that addresses the years patients often spend with unrecognized joint symptoms before any therapy starts. By the time Step 1 begins, damage may already be underway.

What psoriatic arthritis is really costing you

Psoriatic arthritis drug costs are only part of the picture. Joint pain, stiffness, and fatigue translate directly into missed work and reduced output — and that's before counting any surgery from the diagnostic delay.

Based on your journey above–adjust the numbers to match your situation.
Work days missed due to joint pain/flares in the last 12 months
Your hourly wage (for lost income calculation)
$
Your estimated total annual cost of psoriatic arthritis $0
Drug out-of-pocket costs $0
Lost income (missed days) $0
Reduced productivity at work (presenteeism) $0
Psoriatic arthritis patients report substantially higher work disability than psoriasis alone; ~140 hrs/yr is a conservative estimate of reduced-output time from active joint disease.4 Drug out-of-pocket costs based on your coinsurance selection for it above (or a typical default if you haven't reached it yet).
If your care reaches the last phase of this journey — IL-17 / IL-23 Inhibitor or JAK Inhibitor
$0
Projected patient out-of-pocket cost for a full year at that phase, given your coinsurance selection for it above (or a typical default if you haven't reached it yet).

What your insurer is paying

Psoriatic arthritis is one of the costliest rheumatic diseases per patient in commercial insurance, driven by biologic pharmacy spend that starts around $30,000/year and climbs further with each drug switch.

Annual Payer Perspective — Commercial Insurance
What your health plan spends on your psoriatic arthritis each year
Based on your treatment journey above · All figures reflect payer (insurer) paid portion, not patient out-of-pocket cost.
Estimated annual payer cost for your psoriatic arthritis care $0
Biologic drug spend (payer portion)
~80% of net price after patient coinsurance; biologics represent the large majority of psoriatic arthritis pharmacy cost
$0
Medical costs (rheumatology visits, imaging, labs)
Baseline non-drug medical costs for a managed psoriatic arthritis patient
~$4,200
Have you had a joint procedure or surgery related to these symptoms?
Surgical cost is a downstream consequence of diagnostic delay, not of the biologic ladder itself — but it lands on the same claims history
All-cause annual healthcare costs for psoriatic arthritis patients run ~$30,000/patient/year — nearly 3× the cost of psoriasis alone, largely driven by biologic pharmacy spend and imaging.
Payer cost projection if care reaches the last phase of this journey — IL-17 / IL-23 Inhibitor or JAK Inhibitor
$0
Estimated annual payer spend at that phase: ~80% of drug price plus baseline medical costs, excluding any flare/crisis event above
⚑ Where the real savings are being missed
Step therapy controls which biologic is tried first — but the biggest avoidable cost sits upstream of it, in the ~5 years of rising claims and elevated surgery rates before psoriatic arthritis is even diagnosed. Faster rheumatology referral, not a different biologic sequence, is where the larger savings opportunity lives.
Understanding Your Risk

What the research shows over time

These outcomes are not inevitable — but they are the documented trajectory for patients who move through conventional-DMARD-then-biologic step therapy without earlier detection of joint disease.

Based on peer-reviewed clinical data
Long-term outcomes for psoriatic arthritis patients on standard step therapy
⏳
7.49 yr mean diagnostic delay reported in a real-world psoriatic arthritis cohort, with symptomatic joint disease going unaddressed the entire time9
🔪
27.4% of patients underwent at least one musculoskeletal surgery during the diagnostic-delay period — at a higher annual rate than after diagnosis9
📈
~5 yr before diagnosis, healthcare costs are already rising — the disease is generating claims long before it has a name10
💊
58–78% ACR20 response achievable with a first-line TNF inhibitor — meaningful relief exists once treatment actually starts5
✦ A different journey exists

Thymos Health offers another way

Conventional psoriatic arthritis care escalates drugs after damage shows up on imaging. Thymos goes further – synthesizing your skin history, joint symptoms, labs, and imaging to flag psoriatic arthritis early and coordinate rheumatology and dermatology around one plan, instead of waiting years for a referral.

✓
Root cause treatment — not just another layer of suppression
✓
Whole system autoimmune specialist quarterbacks your labs, your team, your care plan
✓
24/7 personalized support — not just at your next follow-up in 3 months
✓
80%+ symptom relief within 3 months across autoimmune conditions
No commitment. Takes 2 minutes.
Get Started
Sources & Citations ▼
[1] Derived from Rheumatology Advisor (2024) reporting 30%–33% of the ~8 million Americans with psoriasis also have psoriatic arthritis (≈2.4–2.7 million); undiagnosed psoriatic arthritis reported in 9% of psoriasis patients.
Source: rheumatologyadvisor.com
[2] Diagnostic Delay in Psoriatic Arthritis: A Population-based Study. The Journal of Rheumatology, 2021 (n=164). Median time from symptom onset to physician diagnosis: 2.5 years (IQR 0.5–7.3); diagnosed by 6 months in 23%, by 1 year in 35%, by 2 years in 45%. No improvement in delay 2000–2017.
Source: jrheum.org
[3] What Clinical Factors Affect Length of Transition to Psoriatic Arthritis in Patients With Psoriasis? ACR Open Rheumatology, 2024. Psoriatic arthritis occurs in up to 40% of psoriasis patients; up to 40% of psoriatic arthritis cases were not previously identified even in dedicated screening studies of psoriasis patients.
DOI: 10.1002/acr2.11703
[4] Employer Health Innovation Co., "Soaring Psoriasis: Market Trends and Opportunities for Psoriatic Conditions," 2023. Over the last 10 years, all-cause annual healthcare costs per psoriatic arthritis patient averaged almost $30,000, compared to about $11,000 for plaque psoriasis alone.
Source: employershealthco.com
[5] TNF Inhibitor Therapy for Psoriatic Arthritis (Healio clinical review, citing Mease PJ et al., ADEPT trial, Arthritis Rheum 2005, and Genovese MC et al., J Rheumatol 2007). Etanercept ACR20/50/70 at 12 wks: 59%/38%/11% vs. 15%/4%/0% placebo. Adalimumab (ADEPT) ACR20/50/70 at wk12: 58%/36%/20%.
Source: healio.com
[6] Biologic Therapy chapter, Healio clinical review of psoriatic arthritis trials (SPIRIT-P1/P2, FUTURE 2/5). Response rates for TNF-experienced patients are consistently lower than biologic-naïve patients across trial programs; radiographic progression (change in van der Heijde-modified Total Sharp Score) continues in a meaningful minority of treated patients.
Source: healio.com
[7] Use of IL-17 antagonists to inhibit progression of structural damage in psoriatic arthritis patients (secukinumab FUTURE program pooled analysis). At week 52, ACR20/50/70 (observed analysis) were 69.5%/50.0%/28.2% for secukinumab 10mg/kg IV→150mg SC.
Source: USPTO patent filing citing trial data
[8] Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis (SELECT-PsA 1). New England Journal of Medicine, 2020. Upadacitinib 30mg met noninferiority and superiority criteria vs. adalimumab on ACR20 at week 12.
Source: nejm.org
[9] Increased Musculoskeletal Surgery Rates During Diagnostic Delay in Psoriatic Arthritis: A Retrospective Cohort Study (n=84). Mean diagnostic delay: 7.49 years. 27.4% underwent ≥1 MSK surgery during the delay period, at a significantly higher annual rate (Z=−3.18, p=0.001) than post-diagnosis.
PMC: PMC12071673
[10] Same cohort study (PMC12071673): healthcare costs, driven substantially by MSK surgeries, begin increasing approximately 5 years before an eventual PsA diagnosis.
PMC: PMC12071673